Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
Homologous Ad26.COV2.S vaccination results in reduced boosting of humoral responses in hybrid immunity, but elicits antibodies of similar magnitude regardless of prior infection.
复制标题
同源 Ad26.COV2.S 疫苗接种会导致混合免疫中体液反应的增强减弱，但无论先前是否感染，都会引发相似程度的抗体。
DOI：
10.1101/2023.03.15.23287288
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Menn
中科院分区：
文献类型：
--
作者：
Moyo-Gwete,Thandeka;Richardson,SimoneI;Keeton,Roanne;Hermanus,Tandile;Spencer,Holly;Manamela,NeliaP;Ayres,Frances;Makhado,Zanele;Motlou,Thopisang;Tincho,MariusB;Benede,Ntombi;Ngomti,Amkele;Baguma,Richard;Chauke,MasegoV;Menn
先前的SARS-CoV-2感染对Ad26.COV2.S疫苗引起的应答的持久性的影响，以及同源加强的效果尚未得到很好的研究。我们在接受Ad26.COV2.S疫苗接种后对一组医疗工作者进行了6个月的随访，并在接受Ad26.COV2.S加强剂量后再随访了一个月。我们评估了从未感染过SARS-CoV-2的个体与接种疫苗前感染过D614G或Beta变体的个体的纵向刺突特异性抗体和T细胞应答。在6个月随访期内，无论感染史如何，初次给药引起的抗体和T细胞应答对几种相关变体具有持久性。然而，在第一次接种疫苗后6个月，具有混合免疫的个体中的抗体结合、中和和ADCC比先前没有感染的个体高59倍。先前感染组的抗体交叉反应性在6个月时相似，与早期时间点不同，表明免疫印迹的影响在6个月时减弱。重要的是，Ad26.COV2.S加强剂量将先前未感染的个体中的抗体应答的幅度增加到与先前感染的个体相似的水平。尖峰T细胞应答的幅度和T细胞应答者的比例在同源加强后保持稳定，伴随着长寿命的早期分化的CD4记忆T细胞的显著增加。因此，这些数据强调了多种抗原暴露，无论是通过感染和疫苗接种还是单独疫苗接种，都会在Ad26.COV2.S疫苗接种后导致类似的增强。
The impact of previous SARS-CoV-2 infection on the durability of Ad26.COV2.S vaccine-elicited responses, and the effect of homologous boosting has not been well explored. We followed a cohort of healthcare workers for 6 months after receiving the Ad26.COV2.S vaccine and a further one month after they received an Ad26.COV2.S booster dose. We assessed longitudinal spike-specific antibody and T cell responses in individuals who had never had SARS-CoV-2 infection, compared to those who were infected with either the D614G or Beta variants prior to vaccination. Antibody and T cell responses elicited by the primary dose were durable against several variants of concern over the 6 month follow-up period, regardless of infection history. However, at 6 months after first vaccination, antibody binding, neutralization and ADCC were as much as 59-fold higher in individuals with hybrid immunity compared to those with no prior infection. Antibody cross-reactivity profiles of the previously infected groups were similar at 6 months, unlike at earlier time points, suggesting that the effect of immune imprinting diminishes by 6 months. Importantly, an Ad26.COV2.S booster dose increased the magnitude of the antibody response in individuals with no prior infection to similar levels as those with previous infection. The magnitude of spike T cell responses and proportion of T cell responders remained stable after homologous boosting, concomitant with a significant increase in long-lived early differentiated CD4 memory T cells. Thus, these data highlight that multiple antigen exposures, whether through infection and vaccination or vaccination alone, result in similar boosts after Ad26.COV2.S vaccination.